Aspen - $JSEAPN - considering that it costs R140 - R170, and acc for the nos of those on ventilators Dexamethasone might not be a rev. boon. However other elements of its portfolio could drive up earnings. Currently it's at technical level #JSE #STOCKS  https://t.co/mldURXF17z